Mechanisms and possible hepatoprotective effects of glucagon-like peptide-1 receptor agonists and other incretin receptor agonists in non-alcoholic fatty liver disease
G Targher, A Mantovani, CD Byrne - The lancet Gastroenterology & …, 2023 - thelancet.com
Summary Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic
polypeptide (GIP) are incretins that stimulate insulin secretion from pancreatic β cells in …
polypeptide (GIP) are incretins that stimulate insulin secretion from pancreatic β cells in …
[HTML][HTML] GLP-1 and GIP receptor signaling in beta cells–a review of receptor interactions and co-stimulation
A Mayendraraj, MM Rosenkilde, LS Gasbjerg - Peptides, 2022 - Elsevier
Glucagon-like peptide 1 receptor (GLP-1R) and glucose-dependent insulinotropic
polypeptide receptor (GIPR) are two class B1 G protein-coupled receptors, which are …
polypeptide receptor (GIPR) are two class B1 G protein-coupled receptors, which are …
What turns CREB on? And off? And why does it matter?
A Steven, M Friedrich, P Jank, N Heimer… - Cellular and Molecular …, 2020 - Springer
Altered expression and function of the transcription factor cyclic AMP response-binding
protein (CREB) has been identified to play an important role in cancer and is associated with …
protein (CREB) has been identified to play an important role in cancer and is associated with …
GIP and GLP‐1, the two incretin hormones: similarities and differences
Y Seino, M Fukushima, D Yabe - Journal of diabetes …, 2010 - Wiley Online Library
Gastric inhibitory polypeptide (GIP) and glucagon‐like peptide‐1 (GLP‐1) are the two
primary incretin hormones secreted from the intestine on ingestion of glucose or nutrients to …
primary incretin hormones secreted from the intestine on ingestion of glucose or nutrients to …
Genetically engineered pigs as models for human disease
C Perleberg, A Kind… - Disease models & …, 2018 - journals.biologists.com
Genetically modified animals are vital for gaining a proper understanding of disease
mechanisms. Mice have long been the mainstay of basic research into a wide variety of …
mechanisms. Mice have long been the mainstay of basic research into a wide variety of …
The role of incretins in glucose homeostasis and diabetes treatment
W Kim, JM Egan - Pharmacological reviews, 2008 - ASPET
Incretins are gut hormones that are secreted from enteroendocrine cells into the blood within
minutes after eating. One of their many physiological roles is to regulate the amount of …
minutes after eating. One of their many physiological roles is to regulate the amount of …
Two incretin hormones GLP-1 and GIP: comparison of their actions in insulin secretion and β cell preservation
D Yabe, Y Seino - Progress in biophysics and molecular biology, 2011 - Elsevier
Gastric inhibitory polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) are the two primary
incretin hormones secreted from the intestine upon ingestion of glucose or nutrients to …
incretin hormones secreted from the intestine upon ingestion of glucose or nutrients to …
Endogenous hindbrain glucagon-like peptide-1 receptor activation contributes to the control of food intake by mediating gastric satiation signaling
Exogenous activation of central nervous system glucagon-like peptide-1 (GLP-1) receptors
(GLP-1Rs) reduces food intake. Experiments addressed whether endogenous central GLP …
(GLP-1Rs) reduces food intake. Experiments addressed whether endogenous central GLP …
Glucose‐dependent insulinotropic polypeptide (gastric inhibitory polypeptide; GIP)
CHS McIntosh, S Widenmaier, SJ Kim - Vitamins & Hormones, 2009 - Elsevier
Glucose‐dependent insulinotropic polypeptide (GIP; gastric inhibitory polypeptide) is a 42
amino acid hormone that is produced by enteroendocrine K‐cells and released into the …
amino acid hormone that is produced by enteroendocrine K‐cells and released into the …
Role of the cAMP pathway in glucose and lipid metabolism
K Ravnskjaer, A Madiraju, M Montminy - Metabolic Control, 2016 - Springer
Abstract 3′–5′-Cyclic adenosine monophosphate (cyclic AMP or cAMP) was first
described in 1957 as an intracellular second messenger mediating the effects of glucagon …
described in 1957 as an intracellular second messenger mediating the effects of glucagon …